drugset / Trial / NCT01418742
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Phase 2
Terminated
11 enrolled
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
ClinAssess · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxycycline | Small molecule | 100 mg | Oral |
| Comparator | Panitumumab | Monoclonal antibody | — | — |